The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Impaired immunity in DLBCL survivors
Tanaya Shree
• 2 Jul 2019
Survivors of diffuse large B-cell lymphoma (DLBCL) may experience impaired immune health, as discussed here by Tanaya Shree, MD, Stanford University Medical Center, California, CA, who explains the results of a large population-based study. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
